The results of the world's first human clinical trial of the new crown vaccine have been released

On the evening of May 22, The Lancet published online the results of the world's first human clinical trial of the new coronavirus, showing that the recombinated adenovirus type 5 vector new crown vaccine is safe during Phase I clinical trials and can produce an immune response to the new coronavirus in the human body. The results came from Chen Wei, a member of the Institute of Bioengineering at the Institute of Military Medicine of the Academy of Military Sciences, and Professor Zhu Fengcai of the Jiangsu Provincial Center for Disease Control and Prevention.test results showed that 108 volunteers did not experience serious adverse events within 28 days of neo-coronary vaccination of recombinated adenovirus type 5 vectors. ELISA antibodies and nalized antibodies increased significantly on the 14th day and peaked 28 days after vaccination. Specific T-cell response peaks on the 14th day after vaccination.
Chen Wei said the results were an important milestone in proving that the recombinated adenovirus type 5 vector new coronary vaccine is a potential candidate vaccine.results, published today, assessed the subjects for only 28 days, and the final results will be based on a six-month assessment of the subjects' condition.
the trial used different doses of the new recombinated adenovirus type 5 vector new crown vaccine for 108 healthy adults aged 18 to 60 who were not infected with the new coronary pneumonia virus, and assessed the safety and effectiveness of the vaccine's immune response.
subjects were divided into three groups on average, with recombinated adenovirus type 5 carrier neo-coronary vaccine in low doses (5×1010 virus particles/0.5 ml), medium doses (1×1011 virus particles/1.0 ml) or high doses (1.5×1011 virus particles/1.5 ml). Since then, researchers have regularly tested the volunteers' blood to determine whether the vaccine stimulates antibodies and T-cell reactions that fight the new coronary pneumonia virus.
found that the most common adverse reactions at the injection site were pain, and the most common systemic adverse reactions were fever, fatigue, headache and muscle pain. One subject with a high dose of the vaccine reported severe fever and severe symptoms such as fatigue, shortness of breath and muscle pain, but these adverse reactions lasted less than 48 hours.
within two weeks of vaccination, all dose levels of the vaccine triggered some degree of immune response, and some subjects detected a mesobacterial antibody against the new coronavirus. After 28 days, the binding antibodies of most subjects increased fourfold, and half of the subjects in the medium and low dose groups and three quarters of the subjects in the high-dose group showed meso-antibodies against the new coronavirus.
, more than 100 candidates for the new coronary pneumonia vaccine are currently under development worldwide. The random, double-blind, placebo-controlled recombinant adenovirus type 5 vector new coronary vaccine was launched in Phase II clinically in Wuhan to determine whether the results could be repeated and whether any adverse events would occur within 6 months of vaccination. Phase II also included subjects over the age of 60 for the first time. (Source: Li Chenyang, China Science Journal)
relevant paper information: